4D Molecular Therapeutics, Inc. (FDMT)

Several events impacted FDMT's stock price in the past six months. The company reported its second-quarter 2025 earnings, which missed consensus estimates. Roth Capital adjusted its price objective for 4D Molecular Therapeutics from $44.00 to $38.00, while maintaining a "buy" rating. 4D Molecular Therapeutics announced a 25% reduction in its workforce to offset expenses and focus on late-stage development. Weiss Ratings reaffirmed a "sell (d-)" rating for the company's stock. The Cystic Fibrosis Foundation committed up to an additional $11 million in equity funding to accelerate the development of 4D-710. Insider Scott Bizily sold shares of the company's stock. The stock reached a new 12-month high. Royal Bank of Canada reissued an "outperform" rating and set a $26.00 price objective for the shares. Insider Scott Bizily exercised stock options and subsequently sold common shares. Shares of FDMT traded up 20.4%, reaching $12.04 during mid-day trading.

As a clinical-stage biotherapeutics company, 4D Molecular Therapeutics' progress and perceived value are driven by milestones such as the advancement of product candidates through clinical trial phases, successful clinical trial results, regulatory approvals, securing funding and partnerships, and analyst ratings and investor sentiment, rather than traditional consumer demand seasonality.

4D Molecular Therapeutics, Inc. (FDMT) is a clinical-stage biotherapeutics company focused on developing genetic medicines through its therapeutic vector evolution platform. The company operates in the Biotechnology industry, specifically in the Biological Products sector, and concentrates its research and development on ophthalmology, cardiology, and pulmonology. Its major product candidates include 4D-150, designed for blinding retinal vascular diseases, and 4D-710, a genetic medicine for cystic fibrosis patients.

4D Molecular Therapeutics conducts its operations primarily in the United States, specifically in Emeryville, California, and also has a presence in the Netherlands.

4D Molecular Therapeutics has received a "Moderate Buy" consensus rating from eleven brokerage firms, with an average 12-month target price of $29.50; however, Weiss Ratings issued a "sell (d-)" rating in October 2025. The company's decision in July 2025 to reduce its workforce by 25% could impact its reputation.

Institutional investors and hedge funds hold a significant majority of 4D Molecular Therapeutics' stock, owning 99.27% of the company, while corporate insiders own 3.85%. Major institutional owners include BVF Inc. IL, Federated Hermes Inc., Millennium Management LLC, Assenagon Asset Management S.A., Raymond James Financial Inc., Russell Investments Group Ltd., Farther Finance Advisors LLC, American Century Companies Inc., Proficio Capital Partners LLC and Dynamic Technology Lab Private Ltd.